HOPO 14-1: Groundbreaking Oral Radioprotective Chelator

Nuclear and radiological emergencies present formidable clinical challenges for mass decorporation of internalized radionuclides. The first-in-human clinical evaluation of an oral actinide chelator, HOPO 14-1, marks a historic milestone in public health preparedness. Currently, clinical teams rely on diethylenetriamine pentaacetate formulations to clear internal contamination. However, these older agents require intravenous infusion or nebulization by skilled clinicians. Consequently, stockpiling and rapidly distributing injectable therapies during large-scale contamination remains a critical bottleneck. The novel agent HOPO 14-1 addresses this vulnerability by offering a shelf-stable oral capsule.

Study Design and Single Ascending Dose Escalation

Investigators conducted a Phase 1 nonrandomized clinical trial across 42 healthy adult volunteers in the United States. Furthermore, researchers evaluated seven ascending single-dose cohorts ranging from 100 mg up to 7500 mg. Each cohort enrolled six healthy participants who received a single oral dose of HOPO 14-1. Afterward, clinicians followed participants closely for 14 days to monitor safety, tolerability, and pharmacokinetics. In addition, the team tracked cumulative excretion pathways in both urine and feces.

Safety Profile and Tolerability Findings

Reassuringly, the study recorded no serious adverse events and no dose-limiting toxic effects across all tested doses. Most reported drug-related events were mild to moderate in severity. Specifically, adverse reactions included transient diarrhea, vomiting, headache, and fatigue. Gastrointestinal symptoms occurred primarily at the highest dose levels, defining the practical single-dose ceiling. Therefore, the overall safety profile supports further clinical progression into multidose and efficacy protocols.

Pharmacokinetics and Excretion Dynamics

Pharmacokinetic analyses revealed rapid oral absorption across all dose tiers. Indeed, plasma concentrations reached peak levels between 0.86 hours and 1.90 hours following ingestion. Systemic drug exposure increased in a dose-dependent fashion, showing greater than proportional increases at higher doses. Notably, fecal excretion served as the primary elimination pathway, while urinary clearance remained minimal. This pharmacokinetic behavior highlights efficient systemic clearance and confirms robust oral bioavailability.

Clinical Significance of the First Oral Actinide Chelator

Preclinical studies previously established that HOPO 14-1 binds multiple radionuclides, including plutonium, americium, uranium, and neptunium. In contrast, traditional DTPA chelates a narrower spectrum of radioactive elements. Consequently, this broad-spectrum oral countermeasure provides substantial logistical advantages for national emergency response frameworks. Clinicians and disaster planners can readily deploy oral capsules in mass-exposure scenarios without overwhelming hospital resources. Thus, HOPO 14-1 represents a transformative asset for emergency preparedness and environmental toxicology.

Frequently Asked Questions

Q1: What is HOPO 14-1, and how does it work?

HOPO 14-1 is an investigational oral chelator containing 3,4,3-LI(1,2-HOPO). Specifically, it selectively binds internal radionuclides and heavy metals, enabling their safe excretion through the gastrointestinal tract.

Q2: Why is an oral chelator advantageous over current standard therapies?

Currently approved DTPA treatments require intravenous or nebulized administration by trained personnel. In contrast, an oral capsule allows rapid, self-administered distribution during mass-casualty nuclear emergencies.

Q3: What were the most common adverse effects observed in the Phase 1 trial?

Participants reported mild to moderate gastrointestinal adverse events, primarily diarrhea and vomiting at high doses. Importantly, investigators observed no dose-limiting toxicities or serious adverse events.

References

1. Goonewardena SN et al. HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial. JAMA. 2026 Nov 11. doi: 10.1001/jama.2026.19809. PMID: 43013314.
2. National Institutes of Health. First-in-human trial of oral drug to remove radioactive contamination begins. NIH News Releases. 2023.
3. Abergel RJ, Durbin PW, Kullgren B, et al. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO). Health Phys. 2010;99(3):401-407.